Diagnostic Microbiology & Infectious Disease
Volume 67, Issue 2 , Pages 191-197 , June 2010

Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii

  • Glenn A. Pankuch

      Affiliations

    • Department of Pathology, Hershey Medical Center, Hershey, PA 17033, USA
    • ,
  • Harald Seifert

      Affiliations

    • Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany
    • ,
  • Peter C. Appelbaum

      Affiliations

    • Department of Pathology, Hershey Medical Center, Hershey, PA 17033, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-717-531-5113; fax: +1-717-531-7953.

Received 11 December 2009 ,Accepted 10 January 2010.

References 

  1. Bajaksouzian S, Visalli MA, Jacobs MR, Appelbaum PC. Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against Acinetobacters determined by checkerboard and time–kill studies. Antimicrob. Agents Chemother. 1997;41:1073–1076
  2. Cappelletty DM, Rybak MR. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1996;40:677–683
  3. Clinical and Laboratory Standards Institute (CLSI) . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - eighth edition, M07-A8. Wayne, PA: CLSI; 2009;
  4. Credito K, Lin G, Appelbaum PC. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus by time–kill methodology. Antimicrob. Agents Chemother. 2007;51:1504–1507
  5. Eliopoulos GM, Moellering RC. Antimicrobial combinations. In:  Lorian V editors. Antibiotics in laboratory medicine. Baltimore: Williams and Wilkins; 1991;p. 432–492
  6. Falagas ME, Koletski PK, Bliziotis IA. The diversity of definitions of multi-drug resistant (MDR) and pandrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. J. Med. Microbiol. 2006;55:1619–1629
  7. Fisher RA. Statistical methods, experimental design and scientific inference. New York: Oxford University Press, Inc; 1990;
  8. Grundmann HJ, Towner KJ, Dijkshoorn L, Gerner-Smidt P, Maher M, Seifert H, et al. Multicenter study using standardized protocols and reagents for evaluation of reproducibility of PCR-based fingerprinting of Acinetobacter spp. J. Clin. Microbiol. 1997;35:3071–3077
  9. Hilliard JJ, Fernandez J, Melton JI, Foleno B, Wira E, Lynch AS, et al. Activity of doripenem against Pseudomonas aeruginosa alone and in combination with amikacin, colistin, or levofloxacin. In: Abstr 49th Intersci Conf Antimicrob Agents Chemother. 2009;p. B–1327(abstr)
  10. Hujer KM, Hujer AM, Hulten EA, Bajaksouzian S, Adams JM, Donskey CJ, et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob. Agents Chemother. 2006;50:4114–4123
  11. Kean SJ. Doripenem: a review of its use in the treatment of bacterial infections. Drugs. 2008;68:2021–2057
  12. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R and the BSAC Working Parties on Resistance Surveillance. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001–06. J. Antimicrob. Chemother. 2008;62(Suppl. 2):ii55–ii63
  13. Manual of Clinical Microbiology. In:  Murray PR,  Baron EJ,  Jorgensen JH,  Landry ML,  Pfaller MA editor. Manual of clinical microbiology. 9th ed.. Washington (DC): American Society for Microbiology; 2007;
  14. Marti S, Sanchez-Céspedes J, Alba V, Vila J. In vitro activity of doripenem against Acinetobacter baumannii clinical isolates. Int. J. Antimicrob. Agents. 2009;33:181–182
  15. Pankuch GA, Lin G, Seifert H, Appelbaum PC. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob. Agents Chemother. 2008;52:333–336
  16. Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob. Agents Chemother. 2008;52:4388–4399
  17. Shields RK, Potoski BA, Clancy CJ, Adams-Haduch JM, Doi Y, Kwak EK, et al. Microbiologic and clinical evidence supporting the combination of doripenem and colistin for the treatment of pan-resistant Acinetobacter. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. 2009;E–1459(abstr)
  18. Vaneechoutte ML, Dijkshoorn L, Tjernberg I, Elaichouni de Vos AP, Claeys PG, Verschraegen G. Identification of Acinetobacter genomic species by amplified ribosomal DNA restriction analysis. J. Clin. Microbiol. 1995;33:11–15

PII: S0732-8893(10)00008-8

doi: 10.1016/j.diagmicrobio.2010.01.004

Diagnostic Microbiology & Infectious Disease
Volume 67, Issue 2 , Pages 191-197 , June 2010

Article Tools

* Image Usage & Resolution